K. Pennington

发表

Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas

Sheena M. Scroggins, Rochelle L. Garcia, T. Walsh, 2013, Clinical Cancer Research.

Characteristics of women with ovarian carcinoma who have BRCA1 and BRCA2 mutations not identified by clinical testing.

Rochelle L. Garcia, T. Walsh, Ming K. Lee, 2013, Gynecologic oncology.

Germline mutations in Black patients with ovarian, fallopian tube and primary peritoneal carcinomas.

E. Lengyel, E. Swisher, B. Norquist, 2021, Gynecologic oncology.

Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits.

E. Swisher, M. Laya, B. Norquist, 2019, Gynecologic oncology.

BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma

Rochelle L. Garcia, T. Walsh, M. King, 2013, Cancer.

Inherited mutations in fallopian tube, ovarian and primary peritoneal carcinoma: Changes in diagnoses and mutational frequency over 20 years.

Rochelle L. Garcia, Ming K. Lee, E. Swisher, 2020, Gynecologic oncology.

Patterns and duration of primary and recurrent treatment in ovarian cancer patients with germline BRCA mutations

Rochelle L. Garcia, E. Swisher, H. Gray, 2019, Gynecologic oncology reports.

Perceptions of risk and reward in BRCA1 and BRCA2 mutation carriers choosing salpingectomy for ovarian cancer prevention

E. Swisher, K. Agnew, B. Norquist, 2017, Familial Cancer.

Germline mutations in cancer susceptibility genes in brca1 and brca2 negative families with ovarian and breast cancer

T. Walsh, M. King, Ming K. Lee, 2014 .

Tackling the opioid crisis: Reduced postoperative oral and intravenous opioid use after implementation of an enhanced recovery after surgery (ERAS) program in gynecologic oncology patients

B. Goff, H. Gray, K. Pennington, 2018, Gynecologic Oncology.

Hematological and biochemical action of tiazofurin (NSC 286193) in a case of refractory acute myeloid leukemia.

G. Tricot, K. Pennington, G. Weber, 1987, Cancer research.

Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing

Rochelle L. Garcia, T. Walsh, M. King, 2011, Proceedings of the National Academy of Sciences.

Lessons from the NOVA trial: an editorial on results, biomarkers, and patient selection for PARP inhibition in recurrent ovarian cancer

E. Swisher, B. Norquist, K. Pennington, 2017 .

The role of the endogenous opioid system in polycystic ovary syndrome.

J. Zubieta, R. Pop-Busui, K. Pennington, 2009, Fertility and sterility.

Tumor infiltrating lymphocytes and homologous recombination deficiency are independently associated with improved survival in ovarian carcinoma.

Rochelle L. Garcia, E. Swisher, K. Agnew, 2019, Gynecologic oncology.

Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations.

Rochelle L. Garcia, Ming K. Lee, E. Swisher, 2020, Gynecologic oncology.

Hereditary ovarian cancer: beyond the usual suspects.

E. Swisher, K. Pennington, 2012, Gynecologic oncology.

Clinical characteristics and outcomes of patients with BRCA1 or RAD51C methylated versus mutated ovarian carcinoma.

Rochelle L. Garcia, E. Swisher, K. Agnew, 2017, Gynecologic oncology.

Overall survival in BRCA1 or RAD51C methylated vs mutated ovarian carcinoma following primary treatment with platinum chemotherapy

E. Swisher, K. Agnew, B. Norquist, 2017 .

Evaluation of Intraoperative Assessments in the Management of Endometrial Carcinoma: A Retrospective Quality Assurance Review

Rochelle L. Garcia, M. Rendi, K. Pennington, 2017, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

53BP1 expression in sporadic and inherited ovarian carcinoma: Relationship to genetic status and clinical outcomes.

Rochelle L. Garcia, P. Welcsh, E. Swisher, 2013, Gynecologic oncology.

Revisiting Minimally Invasive Surgery in the Management of Early-Stage Cervical Cancer.

H. Gray, K. Pennington, R. Urban, 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

The feasibility of screening for malnutrition in the outpatient setting and the prevalence of malnutrition in patients with newly-diagnosed ovarian carcinoma

K. Pennington, K. Eurich, A. Deckert, 2022, Gynecologic oncology reports.

Pathologic findings and clinical outcomes in women undergoing risk-reducing surgery to prevent ovarian and fallopian tube carcinoma: A large prospective single institution experience.

Rochelle L. Garcia, E. Swisher, K. Agnew, 2020, Gynecologic oncology.

The role of physical activity in breast and gynecologic cancer survivorship.

A. McTiernan, K. Pennington, 2018, Gynecologic oncology.

Uterine Lavage Identifies Cancer Mutations and Increased TP53 Somatic Mutation Burden in Individuals with Ovarian Cancer

Brendan F. Kohrn, E. Swisher, R. Katz, 2022, Cancer research communications.

An Alternate Diagnostic Algorithm for the Diagnosis of Intraepithelial Fallopian Tube Lesions

Rochelle L. Garcia, Marie E. Perrone, E. Swisher, 2020, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

Trametinib in Patients With NF1-, GNAQ-, or GNA11-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2

Carlos L. Arteaga, R. Gray, K. Flaherty, 2023, JCO precision oncology.

Insulin resistance influences central opioid activity in polycystic ovary syndrome.

J. Zubieta, R. Pop-Busui, V. Padmanabhan, 2011, Fertility and sterility.

Deep sequencing reveals a high rate of temporal heterogeneity of somatic mutations in paired primary and recurrent ovarian carcinomas

Rochelle L. Garcia, T. Walsh, M. King, 2013 .

Perceptions of risk and reward in BRCA1 and BRCA2 mutation carriers choosing salpingectomy for ovarian cancer prevention

E. Swisher, K. Agnew, B. Norquist, 2020, Familial Cancer.